Boston Scientific (XTER:BSX) Beneish M-Score: -2.41 (As of Jun. 26, 2026)


XTER:BSX Boston Scientific Corp XTER:BSX
74 GF Score
Price €39.13
GF Value €90.62
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Beneish M-Score?

Boston Scientific XTER:BSX -1.98% 74 Beneish M-Score is -2.41 as of Jun. 26, 2026. GuruFocus rates XTER:BSX with a GF Score™ of 74/100 and a GF Value™ of €90.62 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 766 Medical Devices & Instruments companies, Boston Scientific ranks worse than 63.71% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.41 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Boston Scientific's Beneish M-Score or its related term are showing as below:

XTER:BSX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.43   Max: -1.76
Current: -2.41

During the past 13 years, the highest Beneish M-Score of Boston Scientific was -1.76. The lowest was -2.83. And the median was -2.43.


Boston Scientific Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Beneish M-Score Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.39 -2.41 -2.46 -2.45 -2.49

Boston Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.43 -2.45 -2.48 -2.49 -2.41

XTER:BSX vs EW, MDT, DXCM: Beneish M-Score Comparison

For the Medical Devices subindustry, Boston Scientific's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Beneish M-Score falls into.


XTER:BSX
74GF Score
Boston Scientific Corp XTER:BSX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Boston Scientific for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9663+0.528 * 0.9928+0.404 * 0.9874+0.892 * 1.0877+0.115 * 0.9924
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9688+4.679 * -0.016317-0.327 * 0.8807
=-2.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €2,618 Mil.
Revenue was 4500.595 + 4514.244 + 4315.38 + 4387.887 = €17,718 Mil.
Gross Profit was 3125.245 + 3141.012 + 3017.784 + 2968.608 = €12,253 Mil.
Total Current Assets was €7,512 Mil.
Total Assets was €38,364 Mil.
Property, Plant and Equipment(Net PPE) was €3,514 Mil.
Depreciation, Depletion and Amortization(DDA) was €1,198 Mil.
Selling, General, & Admin. Expense(SGA) was €6,078 Mil.
Total Current Liabilities was €3,954 Mil.
Long-Term Debt & Capital Lease Obligation was €9,505 Mil.
Net Income was 1159.965 + 573.888 + 643.26 + 690.999 = €3,068 Mil.
Non Operating Income was 153.97 + -239.974 + -22.152 + 77.163 = €-31 Mil.
Cash Flow from Operations was 301.02 + 1164.856 + 1144.236 + 1114.962 = €3,725 Mil.
Total Receivables was €2,491 Mil.
Revenue was 4313.275 + 4355.755 + 3792.309 + 3827.48 = €16,289 Mil.
Gross Profit was 2969.25 + 2955.725 + 2610.197 + 2647.65 = €11,183 Mil.
Total Current Assets was €6,785 Mil.
Total Assets was €37,130 Mil.
Property, Plant and Equipment(Net PPE) was €3,549 Mil.
Depreciation, Depletion and Amortization(DDA) was €1,198 Mil.
Selling, General, & Admin. Expense(SGA) was €5,767 Mil.
Total Current Liabilities was €4,679 Mil.
Long-Term Debt & Capital Lease Obligation was €10,111 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2618.355 / 17718.106) / (2491.025 / 16288.819)
=0.147778 / 0.152929
=0.9663

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(11182.822 / 16288.819) / (12252.649 / 17718.106)
=0.686534 / 0.691533
=0.9928

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7511.66 + 3514.495) / 38363.615) / (1 - (6784.875 + 3549.225) / 37129.5)
=0.712588 / 0.721674
=0.9874

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17718.106 / 16288.819
=1.0877

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1197.59 / (1197.59 + 3549.225)) / (1198.021 / (1198.021 + 3514.495))
=0.252293 / 0.254221
=0.9924

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6077.905 / 17718.106) / (5767.381 / 16288.819)
=0.343034 / 0.35407
=0.9688

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9504.62 + 3953.915) / 38363.615) / ((10111.175 + 4678.65) / 37129.5)
=0.350815 / 0.398331
=0.8807

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3068.112 - -30.993 - 3725.074) / 38363.615
=-0.016317

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Boston Scientific has a M-score of -2.47 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.41 mean?
Boston Scientific (XTER:BSX) has a Beneish M-Score of -2.41 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Boston Scientific and its competitors. According to the industry distribution chart, Boston Scientific ranks #488 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 63.7%.
Is Boston Scientific's Beneish M-Score too high?
Boston Scientific's current Beneish M-Score is -2.41. Based on the distribution chart, Boston Scientific ranks #488 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boston Scientific has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Beneish M-Score compare to EW and MDT?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #488 out of 766 companies for Beneish M-Score. This places Boston Scientific in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Boston Scientific and its competitors. Boston Scientific's current Beneish M-Score is -2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (XTER:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is €90.62, compared to a current price of €39.13 — trading 56.8% below its estimated fair value. The current Beneish M-Score is -2.41. Boston Scientific's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Boston Scientific (XTER:BSX), the current Beneish M-Score is -2.41 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (XTER:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of €39.13 is trading 56.8% below its estimated GF Value™ of €90.62. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for XTER:BSX:

  • Beneish M-Score: -2.41
  • GF Value™: €90.62 vs. price of €39.13 (56.8% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the XTER:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
74GF Score

Get the complete analysis for XTER:BSX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.13
Price
€90.62
GF Value